Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Is Eli Lilly's 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
12:00pm, Friday, 08'th Aug 2025
Industry pioneer Novo Nordisk A/S NYSE: NVO saw its stock drop nearly 22% on July 29 after lowering its full-year guidance. Then, on Aug. 7, Eli Lilly NYSE: LLY shares fell approximately 14%.
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
12:00pm, Friday, 08'th Aug 2025
LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Eli Lilly: 50% Upside For LLY Stock?
09:55am, Friday, 08'th Aug 2025
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This pos
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
08:47am, Friday, 08'th Aug 2025
Eli Lilly (LLY -14.23%) stock is down big this year. It has lost 17% of its value thus far in 2025 (returns as of Aug. 7).
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
09:45pm, Thursday, 07'th Aug 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti
S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results
06:25pm, Thursday, 07'th Aug 2025
Major U.S. equities indexes were mixed Thursday after the overnight onset of President Trump's "reciprocal" tariffs, which increased the levies imposed on imports from a broad range of trading partner
Eli Lilly's oral obesity treatment efficacy falls short of expectations, says BMO's Evan Seigerman
06:13pm, Thursday, 07'th Aug 2025
Evan Seigerman, BMO, joins 'Fast Money' to talk the latest oral obesity treatment data out of Eli Lilly.
LLY Plunges on Earnings & Weight Loss Drug Disappointment, Outlook Still Holds Optimism
06:00pm, Thursday, 07'th Aug 2025
"This market is priced for perfection," says Rebecca Walser (@walserwealth) and it caused investors to see any red mark on Eli Lilly's (LLY) earnings as bearish. The stock plunged when its oral weight
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
03:11pm, Thursday, 07'th Aug 2025
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used f
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
02:59pm, Thursday, 07'th Aug 2025
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down
02:45pm, Thursday, 07'th Aug 2025
Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall St
Why Eli Lilly Stock Is Plunging Today
01:53pm, Thursday, 07'th Aug 2025
Shares of Eli Lilly (LLY -14.29%) were plunging 14.8% as of 11:14 a.m. ET on Thursday.
Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment
01:14pm, Thursday, 07'th Aug 2025
Eli Lilly delivered strong Q2 results, raising full-year guidance, but shares plunged over 15% due to underwhelming Orforglipron weight loss data. Tirzepatide's explosive growth cements Lilly's domina
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
12:35pm, Thursday, 07'th Aug 2025
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
